24
Participants
Start Date
March 5, 2018
Primary Completion Date
December 3, 2018
Study Completion Date
December 17, 2018
MT-6548
Oral tablet
Research site, Aichi
Research site, Chiba
Research site, Fukushima
Research site, Gunma
Research site, Hokkaido
Research site, Hyōgo
Research site, Ibaraki
Research site, Kagoshima
Research site, Nagano
Research site, Okayama
Research site, Okinawa
Research site, Osaka
Research site, Saitama
Research site, Shiga
Research site, Shizuoka
Research site, Yamagata
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
INDUSTRY